Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Ovarian Neoplasms 23Breast Neoplasms 12Prostatic Neoplasms 11Triple Negative Breast Neoplasms 7Fallopian Tube Neoplasms 7Stomach Neoplasms 5Neoplasm Metastasis 5Sarcoma 4Parkinson Disease 4, Autosomal Dominant Lewy Body 4Metastatic Castration-resistant Prostate Cancer 4Fanconi Anemia, Complementation Group D1 4Small Cell Lung Carcinoma 3Neoplasms 3Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Wilms Tumor 2Sarcoma, Ewing 2Rhabdomyosarcoma 2Rhabdoid Tumor 2Pancreatic Neoplasms 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Medulloblastoma 2Lymphoma, Non-Hodgkin 2Histiocytosis, Langerhans-Cell 2Hepatoblastoma 2Glioma 2Ependymoma 2Endometrial Neoplasms 2

Interventions

olaparib 2tetracarboxyphenylporphine 1testosterone enanthate 1testosterone 17 beta-cypionate 1Testosterone Propionate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Castration-Resistant Prostate Carcinoma × olaparib × Clear all
NCT03516812 2025-09-29

Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer

University of Washington

Phase 2 Completed
36 enrolled 14 charts
Genitourinary

Castration-Resistant Prostate Carcinoma

NCT04951492 2025-01-01

Olaparib for the Treatment of Castration Resistant Prostate Adenocarcinoma

University of Washington

Phase 2 Terminated
2 enrolled 9 charts
Genitourinary

Castration-Resistant Prostate Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡